Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation

International Journal of Ophthalmology

Volumn 5, Issue 6, 2012, Pages 719-725

  Sonmez, Kenan ^a   Ozturk, Faruk ^a  

^a Ulucanlar Eye Training and Research Hospital   (Turkey)

Author keywords

Complications; Intraocular pressure; Intravitreal triamcinolone; Risk factors

Indexed keywords

EID: 84879588635     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2012.06.13     Document Type: Article

References (38)

1. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20(3):244-250.
2. Gillies MC, Simpson JM, Luo W, Penfold P., Hunyor AB, Chua W, Mitchell P, Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121(5):667-673.
3. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2):301-304.
4. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
5. Ding X, Li J, Hu X., Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31(5):838-845.
6. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-927.
7. Massin P, Audren F, Haouchine B., Erginay A, Bergmann JF, Benosman R, Caulin C., Gaudric A. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218-224; discussion 224-225
8. Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077 e35.
9. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108(4):765-772.
10. Kok H, Lau C, Maycock N., McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916 e1-1917.
11. Young S, Larkin G, Branley M., Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29(1):2-6.
12. Dierks D, Lei B, Zhang K., Hainsworth DP Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol. 2005;123(11):1563-1569.
13. Gillies MC, Simpson JM, Billson FA, Luo W., Penfold P, Chua W, Mitchell P., Zhu M, Hunyor AB Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336-340.
14. McCuen BW. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91(6):785-788.
15. Schindler RH, Chandler D, Thresher R., Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93(4):415-417.
16. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103(10):1567-1569.
17. Jonas JB, Degenring RF, Kreissig I, Akkoyun I., Kamppeter BA Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112(4):593-598.
18. Smithen LM, Ober MD, Maranan L, Spaide RF Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740-743.
19. Chylack LT, Jr, Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II) Arch Ophthalmol. 1989;107(7):991-997.
20. Hashemi H, Kashi AH, Fotouhi A, Mohammad K. Distribution of intraocular pressure in healthy Iranian individuals: the Tehran Eye Study. Br J Ophthalmol. 2005;89(6):652-657.
21. Klein BE, Klein R, Linton KL Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1992;33(7):2224-2228.
22. Wu SY, Leske MC Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol. 1997;115(12):1572-1576.
23. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573-580.
24. Rhee DJ, Peck RE, Belmont J, Martidis A., Liu M, Chang J, Fontanarosa J., Moster MR Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90(8):999-1003.
25. Galor A, Margolis R, Brasil OM, Perez VL, Kaiser PK, Sears JE, Lowder CY, Smith SD Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114(10):1912-1918.
26. Chin HS, Park TS, Moon YS, Oh JH Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
27. Clark AF, Brotchie D, Read AT, Hellberg P, English-Wright S, Pang IH, Ethier CR, Grierson I. Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. Cell Motil Cytoskeleton. 2005;60(2):83-95.
28. Gillies MC, Kuzniarz M, Craig J., Ball M, Luo W, Simpson JM Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112(1):139-143.
29. Cekic O, Chang S, Tseng JJ, Akar Y., Barile GR, Schiff WM Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol. 2005;139(6):993-998.
30. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141(4):629-637.
31. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26(4):277-281.
32. Jonas JB, Kreissig I, Hugger P., Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87(4):462-468.
33. Jager RD, Aiello LP, Patel SC, Cunningham ET, Jr Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-698.
34. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121(9):1279-1282.
35. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23(5):686-6891.
36. Moshfeghi AA, Scott IU, Flynn HW, Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol. 2004;138(3):489-492.
37. Amato JE, Lee DH, Santos BA, Akduman L. Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflamm. 2005;13(2-3):245-247.
38. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40(1):63-68.